Table 1.

Demographic and clinical characteristics of patients with cutaneous sarcoidosis.

Age at diagnosis; years
Mean (SD)	52.2 (12.5)
Median (range)	54.0 (22.0–77.0)
Sex, n (%)
Male	16 (43%)
Female	21 (57%)
Morphology of cutaneous disease, n (%) *
Specific cutaneous sarcoidosis
Papules	16 (43%)
Plaques and nodules	9 (24%)
Subcutaneous (Darier-Roussy disease)	1 (3%)
Scar-associated	1 (3%)
Non-specific cutaneous sarcoidosis
Erythema nodosum	10 (27%)
Localized involvement, n (%)	14 (38%)
Systemic involvement, n (%)	23 (62%)
Bilateral hilar lymphadenopathy	23 (62%)
-Severe hilar lymphadenopathy (≥stage II)	6 (16%)
-Impaired lung function	11 (30%)
Arthritis	11 (30%)
Splenomegaly	6 (16%)
Uveitis	2 (5%)
Neurosarcoidosis	1 (3%)
Lofgren syndrome	4 (11%)
Disease course, n (%)
Chronic	26 (70%)
Acute	11 (30%)
Management, n (%)
Topical corticosteroids	24 (65%)
Systemic corticosteroids	12 (32%)
NSAID	5 (13%)
Hydroxychloroquine	2 (5%)
Methotrexate	1 (3%)
Azathioprine	1 (3%)
Doxycycline	1 (3%)
Infliximab	1 (3%)

n, number; SD, standard deviation; NSAID, non-steroidal anti-inflammatory drugs.